Therefore, B7-negative AML should be approached differently by adoptive cell transfer (chimeric antigen receptor T cells), leukemia peptide vaccines, or strategies that augment tumor cell immunogenicity and convert “non-inflamed” LMEs to inflammatory ones, such as hypomethylating agents (9, 15). The gene discussed is CD80; the disease is neoplasm.